<DOC>
	<DOCNO>NCT00002879</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effect cladribine previously treat untreated patient mantle cell lymphoma .</brief_summary>
	<brief_title>Cladribine Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy cladribine ( 2-chlorodeoxyadenosine ; 2-CdA ) treatment mantle cell lymphoma ( MCL ) either initial therapy relapsed/refractory disease . II . Determine flow cytometry immunophenotyping blood lymphocyte number patient peripheral blood involvement time diagnosis compare presence absence peripheral blood involvement response data . III . Detect rearrangements involve bcl-1 gene immunoglobulin heavy chain locus molecular technique ( e.g. , polymerase chain reaction , Southern blotting , situ hybridization ) , compare result immunohistochemical demonstration bcl-1 protein expression . VI . Determine proliferative rate MCL immunohistochemistry DNA content flow cytometry . V. Summarize toxic effect associate treatment . OUTLINE : Patients receive cladribine ( 2-chlorodeoxyadenosine ; 2-CdA ) daily 5 day every 4 week maximum 6 course ; response assess every 2 course . Patients complete remission stable disease discontinue treatment follow ; disease progression time remove study . Patients follow every 2 month 1 year , every 4 month 1 year , every 6 month 1 year , annually 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mantle cell lymphoma ( MCL ) require therapy NCCTG pathology review require Repeat biopsy require previously treat patient previously biopsy proven MCL relapse achieve partial complete remission Rebiopsy require patient : Progression previously biopsy proven MCL receive therapy since diagnostic biopsy OR Previously biopsy proven MCL progress achieve less partial remission follow initial therapy Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST great 3 time normal ( 5 time normal liver involvement ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled hypertension No unstable angina No active congestive heart failure No myocardial infarction within 6 month No serious uncontrolled arrhythmia Other : No active uncontrolled infection No HIV antibody No medical psychiatric condition precludes participation No malignancy past 5 year , except carcinoma situ cervix , resect basal cell squamous cell carcinoma skin , prostate cancer remission follow radical retropubic prostatectomy radiation therapy No pregnant nursing woman Negative pregnancy test require fertile woman within 7 day prior entry Effective contraception require fertile patient throughout study least 30 day thereafter PRIOR CONCURRENT THERAPY : Recovered reversible acute toxic effect previous therapy Biologic therapy : Not specify Chemotherapy : At least 4 week since chemotherapy ( 8 week since nitrosoureas mitomycin ) No prior fludarabine , pentostatin , cladribine Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy great 25 % bone marrow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>